ATLANTA, GA—Using inclisiran (Leqvio; Novartis) as soon as possible in the care of patients with atherosclerotic cardiovascular disease (ASCVD) is associated with sustained lowering of LDL cholesterol ...

The update removes the requirement for Leqvio to be used as an adjunct to statin therapy. The Food and Drug Administration (FDA) has approved a labeling update for Leqvio ® (inclisiran) allowing for ...

WASHINGTON, DC — Treatment with inclisiran (Alnylam Pharmaceuticals/the Medicines Company), which suppresses proprotein convertase subtilisin-kexin type 9 (PCSK9) synthesis in the liver, can ...

More patients with hypercholesterolemia at high/very high risk of cardiovascular (CV) events achieved low-density lipoprotein cholesterol (LDL-C) goals with inclisiran compared with placebo, when ...

Please provide your email address to receive an email when new articles are posted on . “The PCSK9 inhibitors have all been given by injection, every 2 to 4 weeks for the fully human monoclonal ...

LISBON, Portugal — Using RNA interference to inhibit proprotein convertase subtilisin kexin type 9 (PCSK9) synthesis lowers levels of atherogenic lipoproteins across the board, new results suggest. At ...

PHILADELPHIA -- A DNA base editing therapy, intended for lifelong lowering of LDL cholesterol, passed initial tests in people with severe, advanced atherosclerotic cardiovascular disease (ASCVD).

Leqvio is a brand-name prescription medication containing the active ingredient inclisiran. A doctor or healthcare professional will administer the medication as an injection under the skin. Original ...